Articles tagged with Cancer Medication
Jason S. Lewis, PhD, has received the 2019 Paul C. Aebersold Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to basic nuclear medicine science. His research focuses on developing radiopharmaceuticals for targeted diagnosis and treatment of cancer.
A plant-based diet followed by a man with Crohn's disease led to complete mucosal healing and remission after removing animal products from his diet. The study supports the idea that high-fiber, plant-based diets may benefit patients with Crohn's disease.
Researchers discovered that DBC1 protein helps regulate normal anti-cancer functions and that restoring its expression can prevent cancer development and increase therapy effectiveness. The study found that maintaining DBC1 levels in cancer cells exposed to certain drugs triggers a substantially increased response to treatment.
A human-on-a-chip model developed by Hesperos, Inc. realistically replicates the responses of cancer treatments, enabling more accurate and efficient preclinical testing. The model demonstrated efficacy and toxicity of anticancer drugs on various cell lines, informing treatment decisions for individual patients.
Researchers at the University of Copenhagen have developed a new method to map the properties of water in breast cancer cells, which can help understand how chemotherapy drugs work and potentially lead to new treatments. This approach may also be useful for diagnosing other diseases.
Researchers found that administering anti-inflammatory treatments before surgery can eliminate the spread of cancer cells and promote prolonged survival in animal models. These findings suggest a potential paradigm shift in cancer treatment approaches, particularly for patients undergoing resectable cancers.
Researchers found that FOLFIRINOX prolonged patients' lives by an average of 22.2 months, increasing the chances of complete tumor removal through surgery. More than two-thirds of cancers responded well to treatment, allowing for surgical removal.
The Pew Scholars Program in the Biomedical Sciences supports young researchers investigating connections between embryos and their mothers, tick-borne diseases, and sensory information processing. The program aims to drive significant scientific discoveries by investing in promising scientists at the beginning stages of their careers.
CNIO researchers identified new drug combinations that prevent therapy resistance in mice with glioblastoma by targeting the RAS pathway and telomere maintenance. The study found effective synergistic effects and increased life expectancy in mice by up to 80%.
Researchers from the University of Notre Dame have developed small drug-targeting molecules that can deliver potent drugs to desired sites of disease, including cancer. The molecules use a 'homing' cue to attract drug molecules to sites bearing a tumor, reducing toxic side effects.
Scientists have created a hydrogel that attracts chemotherapy drugs to tumors in mice, reducing side effects caused by the drugs acting on healthy cells. The approach uses cucurbituril to target therapies to a tumor, resulting in improved treatment outcomes and reduced toxicity.
Researchers have identified a potential treatment for leukemia by repurposing a heart failure medication. The study found that proscillaridin A preferentially attacks leukemic stem cells, driving the spread of cancer.
Scientists create synthetic metabolic pathway to access essential isoprenoids, overcoming challenges in extraction, cultivation and cost. This breakthrough enables researchers to produce these valuable molecules directly from microbes.
Boehringer Ingelheim and the University of Dundee have extended their collaboration to develop novel protein degradation medicines targeting cancer-causing proteins. The structure-based design approach has yielded a highly potent and selective drug candidate, making it freely available via Boehringer Ingelheim's open innovation portal.
Scientists have discovered a small molecule drug that can stop cancer cells from becoming resistant to chemotherapy. The compound, JH-RE-06, works by thwarting cancer's ability to survive and adapt to DNA damage caused by traditional chemotherapy drugs like cisplatin.
SMU researchers develop a new approach to treat drug-resistant prostate cancer cells using a protein inhibitor and chemotherapy. The method shows promising results, increasing sensitivity of cancer cells to chemotherapeutics without harming healthy cells.
Researchers discovered a compound that blocks a DNA repair pathway, increasing cell killing with cisplatin and preventing mutations. In mouse models, tumors shrank more when treated with the combination of the compound and cisplatin, suggesting improved treatment outcomes.
Recent advances in organoid technology are revolutionizing cancer research, allowing for personalized drug testing on individual patient cells. Meanwhile, integrating organoids with organ-on-a-chip technology may overcome control challenges and enhance physiological realism, paving the way for more advanced biomedical applications.
A researcher is using a $2.3 million grant to study the mechanisms by which bacteria in the colon may trigger cancer development. The goal is to develop prevention strategies, such as probiotics, to stop the triggering of the immune response.
Researchers at Université de Montrêal discovered a molecular indicator for cancer progression, enabling precision medicine. They found that SRC kinases chemically modify SOCS1, leading to uncontrolled cell proliferation in cancers.
A UCLA-led study found that combining hormone therapy with the drug ribociclib significantly improved overall survival in premenopausal women with advanced hormone-receptor positive breast cancer. The study showed a 70% survival rate after 42 months compared to 46% for those receiving only hormone therapy.
A new test developed by UT Southwestern Medical Center aims to identify kidney cancer patients most likely to benefit from immunotherapy. The test uses a diagnostic tracer to visualize tumors and assess PD-L1 expression, which can predict treatment response. The approach has shown promise in early studies.
The POLO trial shows that olaparib significantly reduces the risk of disease progression or death in metastatic pancreatic cancer patients with BRCA mutations. Progression-free survival was 7.4 months on the olaparib arm, compared to 3.8 months on the placebo arm.
Researchers at Fred Hutchinson Cancer Center have successfully treated cancer patients with HIV using immunotherapy drug pembrolizumab. The study found that the drug was safe and effective in patients with well-controlled HIV, offering hope for inclusivity in future clinical trials.
The NCI-MATCH trial found a combination of dabrafenib and trametinib to be effective in treating patients with BRAF mutations across 17 distinct tumor types, including several rare cancer types. The treatment showed promising activity outside of currently approved FDA indications.
A phase III international clinical trial found that treatment with apalutamide significantly improved overall survival by 33% compared to standard-of-care therapy. The study also showed apalutamide delayed disease progression, increasing the time until chemotherapy was needed.
A large study has demonstrated that enzalutamide improves outcomes for men with metastatic hormone-sensitive prostate cancer, with an overall survival rate of 80% after three years. This new treatment option is especially relevant for men who cannot tolerate chemotherapy and have a lower burden of disease.
Researchers have found a safer way to treat T-ALL, a type of leukemia mainly affecting children. The breakthrough involves targeting specific versions of the gamma-secretase complex, which stops cancer growth without causing toxicity.
A recent study published in The FASEB Journal found that some cancer cells switch to alternative molecular mechanisms to evade anti-cancer therapies. Researchers identified several existing and new drugs that specifically target these 'cancer cell escape routes'.
A study by Washington University School of Medicine and Veterans Affairs St. Louis Health Care System found a 17% increased risk of death among people taking proton pump inhibitors (PPIs) for up to 10 years, with deaths attributed to cardiovascular disease, chronic kidney disease, and upper gastrointestinal cancer.
Boosting type 1 interferon production has been shown to clear viral infections and increase immunity against cancer in an animal model. Glycolysis-derived lactate plays a critical role in limiting RLR signaling, which enables the activation of type 1 IFN production.
Researchers identified a genetic switch in breast cancer cells that boosts Keratin-80 production, making cells more rigid and prone to invade nearby tissues. The study suggests targeting this switch with a different drug could help reverse resistance and prevent cancer spread.
A new study presented at ASCO 2019 shows that brigatinib is effective in patients who have received another next-generation ALK inhibitor. The 40-50 percent response rate suggests that brigatinib may be a useful treatment option for these patients. Detailed molecular analyses will help determine the characteristics of patients sensitiv...
Researchers found that the combination of ibrutinib and venetoclax was highly effective in achieving complete remission with undetectable minimal residual disease in high-risk CLL patients. The study also showed that this combination therapy had no new toxic effects compared to individual agents.
A team of researchers developed a macrocyclic peptide, HiP-8, that selectively inhibits active Hepatocyte Growth Factor (HGF), a protein promoting cancer cell invasion and survival. HiP-8 shows high affinity for HGF and has potential as a PET imaging probe and anti-cancer drug.
Researchers have discovered a new treatment approach for T-cell acute lymphoblastic leukemia (T-ALL) that targets the Notch signaling pathway with greater safety and efficacy than previous treatments. The findings, published in Science Translational Medicine, show promise for translating this therapy to patients.
A new urology care model developed by Flinders University focuses on supporting bladder cancer patients' partners and family, addressing their daily impacts and needs. Health professionals can capitalize on this by providing clear information, counseling, and support to manage the shock, fear, and treatment of bladder cancer.
The partnership aims to increase HPV vaccine uptake, which causes over 33,000 cancers annually. UVA will launch a multipronged campaign to educate healthcare workers and the public on the importance of HPV vaccination.
Researchers at University of Virginia Health System are using a unique approach to understand cell communication via pannexin channels. By discovering how cells communicate, they aim to manipulate the channels to better treat major health threats such as high blood pressure and fatty liver disease.
A recent study found that children with cancer wait an average of 6.5 years longer than adults to access new drugs. Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center are advocating for improved pediatric trial timelines. The delay can lead to a lack of effective treatments for life-threatening diseases.
A recent study published in Journal of Thoracic Oncology found that about 3% of brigatinib patients experience shortness of breath within hours of starting the drug. However, with appropriate supportive care, most patients can rapidly build tolerance and continue on the drug without incident.
Researchers at VCU Massey Cancer Center have made a significant discovery regarding tumor dormancy, a state of inactivity that allows cancer cells to evade detection and recurrence. By targeting senescent cells, they hope to develop novel therapeutics that can eliminate dormant tumor cells and prevent disease recurrence.
Researchers have developed a new technique called BiGluc, which enables the visualization of glucose metabolism in real-time in cancerous tumors. This non-invasive imaging method could lead to more effective cancer treatments by identifying the metabolic requirements of different tumors.
A new approach to targeting cancer cells has been developed by UC Riverside researchers, who have found that drugs targeting other amino acids like lysine and tyrosine can be more effective. The study provides novel avenues for deriving potent and selective PPI antagonists
A new genetic basis of a type of brain aneurysm has been identified, suggesting that an existing cancer drug can counter its effects. Researchers have discovered 'gain-of-function variants' in the PDGFRB protein, which causes it to remain locked in a hyper-active form.
A Stanford study of California teens found that owning marketing materials for e-cigarettes and other alternative tobacco products increases their likelihood of trying these products. The study suggests that stricter regulations are needed to restrict such marketing, which can lead to nicotine addiction.
Researchers used CRISPR to analyze over 8,000 gene fusions in human cancer cell lines, finding that 90% do not play an essential role in cancer. A new fusion, YAP1-MAML2, was identified as critical for progression of multiple cancers, offering a potential new drug target.
Researchers discovered that MEK inhibitors activate Wnt signalling pathway in colorectal cancer cells, leading to accumulation of tumor cells with stem cell characteristics. This explains why these drugs are not effective in treating colorectal cancer.
BCL-2 protein deregulation and transcriptional reprogramming contribute to Venetoclax resistance; researchers suggest targeting CDK7 as effective strategy to prevent resistance. Studies provide insights into drug resistance mechanism in B-cell lymphomas, paving way for potential co-treatment strategies.
Researchers developed molecules from the immune system of a parasitic sea lamprey that can deliver anti-cancer drugs directly to brain tumors. The matrix-targeting strategy allows drugs to accumulate in the extracellular matrix, sidestepping cell membrane problems and potentially increasing therapeutic doses.
A Yale study reveals how cediranib, a cancer drug of limited use, stops certain cancer cells from repairing their DNA to survive. The combination of cediranib with olaparib may deliver a lethal blow in cancers that rely on a specific DNA repair pathway.
Researchers have identified a promising therapeutic target for metastatic prostate cancer by inhibiting the PHLPP2 protein, which stabilizes the oncogenic protein MYC. This finding has implications for treating other cancers driven by MYC and could lead to efficient new drugs.
Long-term opiate therapy rates persistently high for at least five years in cancer survivors, increasing over time. Cancer survivors diagnosed later had higher opioid prescribing rates than those diagnosed earlier.
A new study suggests that a probiotic-derived molecule from Bacteroides fragilis can temper the immune system and prevent fatal brain inflammation caused by herpes simplex virus infection. The findings provide an exciting proof of principle for the potential therapeutic benefits of certain prebiotics, probiotics, or synbiotics.
Scientists have identified a promising compound, PHT-7.3, that shrinks KRAS-driven tumors in mice by targeting the protein's partner, Cnksr1. The study provides a potential treatment for KRAS-positive cancers, which currently have no effective therapy.
The Humanwide program at Stanford Medicine combines cutting-edge tools and a collaborative team-based method to provide proactive, personalized care. The pilot program successfully identified previously overlooked health conditions and future health risks in patients, setting them on a path to avoid serious medical problems.
The Damon Runyon Physician-Scientist Training Award provides physicians with research skills and experience to become leaders in translational and clinical research. The award addresses financial burdens that deter physicians from pursuing a research career, offering up to $460,000 over four years.
A new program aims to prevent substance abuse among children and parents, offering tailored classes and social norms campaigns to reduce alcohol and e-cigarette use. The initiative, funded at $1.4 million, also provides referrals to support groups and smoking cessation classes.
Researchers have discovered a new type of drug that targets the genetic weakness in 'diffuse intrinsic pontine glioma', a devastating childhood brain cancer. The treatment also shows promise for patients with stone man syndrome, a rare genetic disease where muscles and ligaments turn to bone. Clinical trials are expected to begin in 2021.
A meta-analysis of 14 studies involving 130,994 patients found that pre-diagnosis statin use reduced the risk of early death from any cause and cancer by 15% and 18%, respectively. Post-diagnosis statin use also showed lower mortality rates